本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海凯淳实业股份有限公司（以下简称"公司"） 于 2024 年 7 月 1 日召开 公司第三届董事会第九次会议，审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金以集中竞价交易方式回购公司部分社会公众股份（以下简 称"本次回购"），用于员工持股计划或股权激励。本次回购股份的资金总额不 低于人民币 1,000.00 万元，不超过人民币 2,000.00 万元，回购价格上限不超过 人民币 27.00 元/股；回购期限自董事会审议通过本次回购股份方案之日起不超 过 12 个月；具体回购股份的数量以回购结束时实际回购的股份数量为准。具体 内容详见公司于 2024 年 7 月 3 日在巨潮资讯网（http://www.cninfo.com.cn） 披露的《关于回购公司股份方案的公告》（公告编号：2024-025）等相关公告。 公司于 2025 年 4 月 18 日召开第三届董事会第十二次会议，审议通过了《关 于增加回购股份资金来源的议案》，同意将回购资金来源由公司自有资金调整为 公司自有资金和/或专项贷款资金 ...

证券代码：301001 证券简称：凯淳股份 公告编号：2025-038 上海凯淳实业股份有限公司 | 本次变动是否存在违反《证 | | | --- | --- | | 券法》《上市公司收购管理 | 是□ 否☑ | | | 办法》等法律、行政法规、 | | | 部门规章、规范性文件和本 如是，请说明违规的具体情况、整改计划和处理措施。 | | | 所业务规则等规定的情况 | | | 5.被限制表决权的股份情况 | | | 按照《证券法》第六十三条 | | | 是□ 否☑ 的规定，是否存在不得行使 | | | 表决权的股份 如是，请说明对应股份数量占现有上市公司股本的比例。 | | | 6.30%以上股东增持股份的进一步说明（不适用） | | | 7.备查文件 | | 1. | 中国证券登记结算有限责任公司持股变动明细； | | 2. | 王莉、徐磊出具的《关于减持股份的告知函》； | | 3. | 深交所要求的其他文件。 | 特此公告。 信息披露义务人：王莉、徐磊 2025 年 6 月 24 日 关于控股股东、实际控制人及一致行动人 减持股份触及 1%整数倍的公告 控股股东、实际控制人王莉女士及一致行动人徐磊先 ...

Group 1 - The company approved a share repurchase plan using its own funds, with a total amount not exceeding RMB 20 million and a maximum repurchase price of RMB 27.00 per share, valid for up to 12 months [1] - The company adjusted the source of repurchase funds to include both its own funds and/or special loan funds, and the maximum repurchase price was revised to RMB 26.625 per share [2] - The company conducted its first share repurchase, acquiring 100,000 shares at a total cost of RMB 2,988,794.00, which complies with the repurchase plan and relevant regulations [3] Group 2 - The company is required to adhere to specific regulations regarding the timing and pricing of share repurchases, including not exceeding the daily trading price limit and avoiding certain trading periods [4]

证券代码：301001 证券简称：凯淳股份 公告编号：2025-037 上海凯淳实业股份有限公司 一、首次回购股份的基本情况 2025 年 6 月 19 日，公司首次通过股票回购专用证券账户以集中竞价交易方 式回购股份，回购股份数量为 100,000 股，占公司目前总股本 80,000,000 股的 0.125%，回购的最高成交价为 30.00 元/股，最低成交价为 29.77 元/股，成交总 金额为 2,988,794.00 元（不含交易费用）。本次回购符合公司回购方案及相关 法律法规的要求。 二、其他说明 关于首次回购公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海凯淳实业股份有限公司（以下简称"公司"） 于 2024 年 7 月 1 日召开 公司第三届董事会第九次会议，审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金以集中竞价交易方式回购公司部分社会公众股份（以下简 称"本次回购"），用于员工持股计划或股权激励。本次回购股份的资金总额不 超过人民币 2,000.00 万元，回购价格上限不超过人民币 27.00 元/股； ...

Core Viewpoint - The company, Kaichun Co., Ltd. (301001), has initiated a share buyback program, reflecting its commitment to enhancing shareholder value through strategic financial management [1] Summary by Relevant Sections Share Buyback Details - The company repurchased 100,000 shares on June 19, 2025, which represents 0.125% of its total share capital of 80 million shares [1] - The highest transaction price for the repurchased shares was 30 CNY per share, while the lowest was 29.77 CNY per share [1] - The total amount spent on the buyback was 2.9888 million CNY, excluding transaction fees [1] Compliance and Future Plans - The buyback is in accordance with the company's buyback plan and relevant legal regulations [1] - The company plans to continue implementing the buyback program within the designated timeframe and will fulfill its information disclosure obligations promptly [1]

Core Viewpoint - The company reported a significant decline in revenue while achieving substantial growth in net profit, indicating a challenging balance between market expansion and cost control [1][2]. Revenue and Profit Discrepancy - The company's revenue decreased to 422 million yuan, a year-on-year decline of 33.91%, primarily due to the weakness in its core business and a significant reduction in brand online sales services [1][2]. - Despite the revenue drop, net profit reached 13 million yuan, reflecting a year-on-year increase of 90.5%, driven by cost control and operational efficiency improvements [1][2]. - The reduction in sales expenses and marketing investments raises concerns about future business growth potential [2]. Research and Development Challenges - The company has shown a worrying trend in R&D investment, with a continuous decrease in R&D expenses and a decline in the number of R&D personnel, indicating insufficient investment in technological innovation [3]. - The focus on operational efficiency over R&D may hinder the company's ability to compete effectively in the beauty e-commerce sector, where technology-driven service capabilities are crucial [3]. - An increase in the number of shareholders and a decrease in share concentration suggest a lack of confidence in the company's future development [3]. Conclusion: Need for Strategic Rebuilding - To achieve sustainable growth, the company must optimize its market strategy by reassessing customer structure and market layout, enhancing competitiveness in the domestic market, and exploring opportunities in emerging markets [4]. - Increasing R&D investment is essential to make technological innovation a core driver of long-term development, thereby enhancing digital service capabilities and market competitiveness [4].

Group 1 - The A-share internet e-commerce sector has experienced a pullback, with Qingmu Technology dropping nearly 9% [1] - Yiwan Yichuang has seen a decline of over 5.5% [1] - Other companies such as Xinghui Co., Kaichun Co., Xinxinda, and Nanji E-commerce also followed the downward trend [1]

Group 1 - Company Gongchuang Turf (605099.SH) stated that the impact of domestic football events on its operations and performance is minimal, as its main business of artificial turf has a low revenue contribution from domestic sports grass [1] - Company Anglikang (002940.SZ) confirmed that its innovative drug project ALK-N001 is still in Phase I clinical trials, indicating a long R&D cycle and significant investment [2] - Company Yiwei Lithium Energy (300014.SZ) plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength and international brand image [3] Group 2 - Company Chaohongji (002345.SZ) also intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to advance its global strategy and improve competitiveness [4] - Company Dexin Technology (603032.SH) clarified that its subsidiary's sales revenue from products used in solid-state battery production is less than 1% of total revenue, emphasizing its focus on quality service [5] - Company Changshan Pharmaceutical (300255.SZ) announced that its application for the marketing authorization of Aibennapeptide injection for type 2 diabetes has been accepted, but the approval timeline remains uncertain [6] Group 3 - Company Baili Electric (600468.SH) reported that its revenue from nuclear fusion-related business is currently minimal, accounting for less than 1% of total revenue [7] - Company Chutianlong (003040.SZ) is exploring digital currency projects but faces risks related to new technology development and commercial application [8] - Company Dongxing Medical (301290.SZ) signed contracts with Shanghai Jiao Tong University for synthetic biology technology development, totaling 6 million yuan, enhancing its R&D capabilities [9] Group 4 - Company Maixinlin (688685.SH) announced that its subsidiary signed contracts for computing power services worth 1.184 billion yuan, expected to positively impact future performance [10] - Company Haichen Pharmaceutical (300584.SZ) reported that its solid-state battery-related business has not yet generated revenue, which does not significantly affect overall performance [11] - Company Filinger (603226.SH) is undergoing stock trading suspension for investigation due to significant price deviations from fundamentals [12] Group 5 - Company Zhongdian Port (001287.SZ) disclosed that the National Integrated Circuit Fund reduced its stake by 1%, now holding 8.97% of the company [13] - Company Huasheng Co., Ltd. (600156.SH) is planning to acquire 100% of Yixin Technology, leading to a stock suspension for up to 10 trading days [14] - Company Jianghuai Automobile reported a 3.52% year-on-year decline in May sales, with new energy vehicle sales down 57.81% [15] - Company Aonong Biological reported a 9.44% year-on-year increase in May pig sales, with a total of 156,200 pigs sold [16]

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

1、本次董事会由董事长王莉女士召集，会议通知于 2025 年 6 月 3 日以专人 送达、电子邮件、电话等通讯方式发出。 2、本次董事会于 2025 年 6 月 6 日在上海凯淳实业股份有限公司（以下简称 "公司"）5 楼元宇宙会议室采取现场结合通讯表决的方式召开。 3、本次董事会应出席 7 人，实际出席会议董事 7 人，其中：现场出席董事 1 人（宋鸣春），以通讯表决方式出席董事 6 人（王莉、徐磊、吴凌东、李祖滨、 厉洋、谢力）。 4、本次董事会由董事长王莉女士主持，公司监事及高级管理人员列席会议。 5、本次董事会会议的召集、召开和表决程序符合法律、行政法规、部门规 章、规范性文件和《公司章程》的规定，合法有效。 证券代码：301001 证券简称：凯淳股份 公告编号：2025-035 上海凯淳实业股份有限公司 第三届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 董事会认为：鉴于近期公司股票价格持续超出回购股份方案拟定的回购价格 上限，基于对公司未来持续稳健发展的信心和对公司投资价值的高度认可，同时 为了 ...